Work

When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

Year: 2024

Type: article

Abstract: In April 2024, the Food and Drug Administration provided accelerated approval for trastuzumab deruxtecan for adult patients with advanced solid tumors which have positive immunochemical staining for HER2 expression, including sarcomas. There should be ample consideration prior to utilization of trastuzumab deruxtecan for patients with sarcomas, as HER2 targeted therapy has been ineffective in certain subtypes.

Source: Cancer

DOI: 10.1002/cncr.35539

Authors: Brian C. Schulte, Caleb Hwang, Andrew E. Horvai, Timothee Olivier

Institutions: University of California, San Francisco, University of California San Francisco Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center, University Hospital of Geneva

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4401864600

FWCI: 0.312

Cites: 29

Cited by: 2

Related to: 10